San Francisco – July 24, 2024 – Cooley advised TD Cowen and Cantor, the placement agents on Palvella Therapeutics’ definitive merger agreement with Pieris Pharmaceuticals and concurrent oversubscribed $78.9 million private financing. BVF Partners, an existing investor, and Frazier Life Sciences, a new investor, co-led the private financing. Palvella and Pieris expect the proposed merger and concurrent private financing to close in the fourth quarter of 2024, subject to stockholder approval of both companies, the effectiveness of a registration statement to be filed with the US Securities and Exchange Commission to register the shares of Pieris common stock to be issued in connection with the merger, and the satisfaction of customary closing conditions.
Partners Denny Won and Kristin VanderPas led the Cooley team advising the placement agents.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.